The FDA-approved imaging agent for detecting coronary artery disease gained Medicare and Medicaid coverage starting April 1.

GE HealthCare Technologies Inc. GEHC recently announced the U.S. launch of Flyrcado (flurpiridaz F 18) injection at the ongoing American College of Cardiology (ACC) Annual Scientific Session & Expo.

The company announced the planned launch of Flyrcado, a radiopharmaceutical product for myocardial perfusion imaging, in April 2025. It is expected to generate $30 million in revenue for 2025 and ...

GE HealthCare has raised the curtain on a new CT system with features designed specifically for addressing cardiovascular ...

GE HealthCare (Nasdaq: GEHC) today announced the U.S. launch of Flyrcado™ (flurpiridaz F 18) injection at the 2025 American ...

Introduced at ACC.25, the Revolution Vibe CT system includes Unlimited One-Beat Cardiac imaging and combines with GE HealthCare’s ECG-less Cardiac, TrueFidelity DL, SnapShot Freeze 2, and Effortless ...

The first patient doses of GE HealthCare’s new FDA-approved PET radiotracer, Flyrcado ™ (flurpiridaz F 18) injection, are being administered at early adopter sites around the United States.

GE HealthCare Technologies Inc. GEHC recently announced the U.S. launch of Flyrcado (flurpiridaz F 18) injection at the ongoing American College of Cardiology (ACC) Annual Scientific Session & Expo.

The much-anticipated Flyrcado™ (flurpiridaz F 18) injection, a first-of-its-kind unit dose positron emission tomography myocardial perfusion imaging agent for the detection of coronary artery ...